

Continued from previous page

**3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000)**

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 172/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 149.47 times i.e. for 61,223,200 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 409,600 Equity to 170 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares applied Category wise	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
6,400	8,991	96.70	57,542,400	93.99	2,400	165:8991	396,000
7,200	152	1.63	1,094,400	1.79	2,400	3:152	7,200
8,000	49	0.53	392,000	0.64	2,400	1:49	2,400
8,800	6	0.06	52,800	0.09	2,400	0:6	-
9,600	29	0.31	278,400	0.45	2,400	1:29	2,400
10,400	4	0.04	41,600	0.07	2,400	0:4	-
11,200	9	0.10	100,800	0.16	2,400	0:9	-
12,000	6	0.06	72,000	0.12	2,400	0:6	-
12,800	14	0.15	179,200	0.29	2,400	0:14	-
13,600	3	0.03	40,800	0.07	2,400	0:3	-
14,400	1	0.01	14,400	0.02	2,400	0:1	-
16,000	5	0.05	80,000	0.13	2,400	0:5	-
17,600	1	0.01	17,600	0.03	2,400	0:1	-
20,000	2	0.02	40,000	0.07	2,400	0:2	-
21,600	1	0.01	21,600	0.04	2,400	0:1	-
22,400	1	0.01	22,400	0.04	2,400	0:1	-
24,000	2	0.02	48,000	0.08	2,400	0:2	-
24,800	1	0.01	24,800	0.04	2,400	0:1	-
25,600	1	0.01	25,600	0.04	2,400	0:1	-
27,200	1	0.01	27,200	0.04	2,400	0:1	-
28,000	3	0.03	84,000	0.14	2,400	0:3	-
29,600	1	0.01	29,600	0.05	2,400	0:1	-
32,000	3	0.03	96,000	0.16	2,400	0:3	-
34,400	5	0.05	172,000	0.28	2,400	0:5	-
40,800	1	0.01	40,800	0.07	2,400	0:1	-
44,000	1	0.01	44,000	0.07	2,400	0:1	-
57,600	1	0.01	57,600	0.09	2,400	0:1	-
80,800	1	0.01	80,800	0.13	2,400	0:1	-
96,000	1	0.01	96,000	0.16	2,400	0:1	-
116,000	1	0.01	116,000	0.19	2,400	0:1	-
290,400	1	0.01	290,400	0.47	2,400	0:1	-
All Allottees	-	0.00	-	-	800	2:170	1,600
<b>TOTAL</b>	<b>9,298</b>	<b>100.00</b>	<b>61,223,200</b>	<b>100.00</b>			<b>409,600</b>

Please Note : 1 lot of 800 shares have been allocated to all the Successful allottees from all the Categories in the ratio of 2:170

**INVESTORS, PLEASE NOTE**

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Kfin Technologies Limited

**TRACK RECORD OF BOOK RUNNING LEAD MANAGER:** The BRLM associated with the Issue has handled 64 Public Issues in the past three financial years, out of which 4 issue was closed below the Issue Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	62	4 (SME)

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:



**KFIN TECHNOLOGIES LIMITED**

Selenium Tower B, Plot 31-32, Gachibowli Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana  
**Telephone:** +91-40-67162222; **Email:** adisoft.ipo@kfinetech.com  
**Investor Grievance Email:** einward.ris@kfinetech.com  
**Contact Person:** M. Murali Krishna, Senior VP  
**SEBI Registration No.:** INR00000221, **CIN:** L72400TG2017PLC117649

On behalf of Board of Directors  
**Adisoft Technologies Limited**  
 Sd/  
**Vaibhav Nandkumar Salunke**  
 Company Secretary and Compliance Officer

Place: Pune, Maharashtra  
 Date: April 29, 2026

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF ADISOFT TECHNOLOGIES LIMITED**

**Disclaimer:** Adisoft Technologies Limited has filed the Prospectus with the RoC on April 28, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLM, Hem Securities Limited at www.hemsecurities.com and the Company at: www.adisoft.co.in and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being Issued and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such Issues and sales are made. There will be no public Issuing in the United States.

**NOTICE**



**Half- Yearly Unaudited Financial results of the schemes of Sundaram Mutual Fund**

Notice is hereby given that, in accordance with Regulation 59 of SEBI (Mutual Funds) Regulations, 1996, read with SEBI Master Circular No. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27 2024, the Unaudited Financial Results of the schemes of Sundaram Mutual Fund for the half year ended March 31, 2026 have been hosted on the website of Sundaram Asset Management Company Limited (the AMC) viz. www.sundarammutual.com

Investors may accordingly view or download the results from the website of the AMC.

Unit holders are advised to update their PAN, KYC details, email address, mobile number, and nominee information with the AMC. They should also ensure that their PAN is linked with their Aadhaar number.

Place: Chennai  
 Date: April 30, 2026

For Sundaram Asset Management Company Limited,  
**R. Ajith Kumar,**  
 Company Secretary & Compliance Officer

For more information please contact:  
**Sundaram Asset Management Company Ltd**  
 (Investment Manager to Sundaram Mutual Fund)  
 CIN: U93090TN1996PLC034615  
**Corporate Office:** 1<sup>st</sup> and 2<sup>nd</sup> Floor, Sundaram Towers, 46, Whites Road, Royapettah, Chennai-14, Toll 1860 425 7237 (India) +91 40 2345 2215 (NRI) www.sundarammutual.com  
 Regd. Office: No. 21, Patullos Road, Chennai 600 002.

**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.**



Corporate Identification No. (CIN) – L55101WB1999PLC090672  
**Registered Office:** "Unirouth House" 3 A, Gurusaday Road, Kolkata - 700019  
 Tel. No.: (91 33) 2283 7964 E-mail: corporate@speciality.co.in  
 Website: www.speciality.co.in

**NOTICE TO SHAREHOLDERS RE-LAUNCH OF SECOND 100-DAY CAMPAIGN "SAKSHAM NIVESHAK"**

Pursuant to the email dated March 27, 2026 communicated by the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA), the Company has launched the Second 100-Day campaign - "Saksham Niveshak" for a period from 1 April, 2026 to 9 July, 2026 to facilitate payment of unclaimed or unpaid dividends directly to rightful shareholders of the Company.

**For Shareholders holding shares in Physical Form:** Kindly update your KYC details / Bank details / choice of nomination / contact information by submitting the Investor Service Request Forms i.e. Form ISR-1, ISR-2, ISR-3, Form SH-13 available on <https://web.in.mgms.mufg.com/KYC-downloads.html>, as applicable and are also requested to convert their physical shares into dematerialized form with the Registrar and Share Transfer Agents (RTA) of the Company i.e. MUGF Intime India Private Limited (Formerly known as Link Intime India Private Limited) at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai -400 083.

**For Shareholders holding shares in Demat Form:** Kindly contact your Depository Participant (DP) for updating KYC and Bank Account details.

All the shareholders are requested to take advantage of this opportunity to update their KYC details, bank mandate, choice of nomination and contact information before 9<sup>th</sup> July, 2026 to ensure smooth receipt of dividends and to prevent their dividend and shares from being transferred to IEPF by furnishing the necessary documents to the Company's Registrar and Transfer Agent i.e. MUGF Intime India Private Limited (Formerly known as Link Intime India Private Limited) at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai -400 083.

The details of unclaimed/ unpaid dividend are available on company's website: <https://www.speciality.co.in/>

**SPECIAL WINDOW FOR TRANSFER OF SHARES**

Pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026, all shareholders are hereby informed that a Special Window is being opened for a period of one year, from February 5, 2026 to February 4, 2027 to facilitate re-lodgement of transfer requests of physical shares.

This facility is available for Transfer deeds lodged prior to April 01, 2019 and which were rejected, returned, or not attended to due to deficiencies in documents/process/or otherwise.

Investors are encouraged to take advantage of this opportunity by furnishing the necessary documents to the Company's Registrar and Transfer Agent i.e. MUGF Intime India Private Limited (Formerly known as Link Intime India Private Limited) at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai -400 083.

The shares that are re-lodged for transfer shall be issued only in dematerialized form, subject to one year lock-in. In case of any queries, shareholders are requested to raise a service request at [mt\\_helpdesk@in.mgms.mufg.com](mailto:mt_helpdesk@in.mgms.mufg.com) or [investor@speciality.co.in](mailto:investor@speciality.co.in) or logging in to SWAYAM Portal on <https://swayam.in.mgms.mufg.com>.

For Speciality Restaurants Limited

**Avinash Kinshikar**  
 Company Secretary & Legal Head  
 (Membership No. FCS - 8364)

Place: Mumbai  
 Date: April 24, 2026



**PIRAMAL PHARMA LIMITED**

CIN: L24297MH2020PLC338592

**Regd. Office:** Gr. Flr., Piramal Ananta, Agastya Corp. Park, Kamani Junction, LBS Marg, Kurla, Mumbai 400070 Maharashtra, India  
**Tel No.:** 022-3820 3000/4000; **Fax No.:** 022-38023884; **Email Id:** shareholders.ppl@piramal.com; **Website:** www.piramalpharma.com

**Extract of Consolidated Financial Results for the Quarter and Year ended March 31, 2026**

Sr. No.	Particulars	Three months ended 31/03/2026	Three months ended 31/12/2025	Corresponding Three months ended 31/03/2025	For the year ended 31/03/2026	For the previous year ended 31/03/2025
		(Refer Note 4)	(Unaudited)	(Refer Note 4)	(Audited)	(Audited)
1	Total Revenue from Operations	2,751.77	2,139.87	2,754.07	8,869.08	9,151.18
2	Earnings before interest, depreciation, tax, share of profit of associates and joint venture and exceptional items for the period (EBITDA)	506.57	238.96	603.02	1,134.92	1,579.64
3	Net Profit / (Loss) for the period (before Tax, share of net profit of associates and Exceptional and/or Extraordinary items)	205.20	(63.02)	256.58	(37.12)	341.71
4	Net Profit / (Loss) for the period before tax (after share of net profit of associates And Exceptional and/or Extraordinary items)	43.00	(93.87)	272.80	(176.06)	414.64
5	Net Profit / (Loss) for the period after tax (after share of net profit of associates And Exceptional and/or Extraordinary items)	(8.82)	(136.20)	153.50	(325.94)	91.13
6	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	154.47	(76.16)	167.45	12.43	170.96
7	Paid-up Equity Share Capital (Face Value Rs.10/- each)	1,327.16	1,325.83	1,323.58	1,327.16	1,324.35
8	Other Equity as shown in the Audited Balance Sheet of the previous year	-	-	-	6,835.46	6,801.12
9	Earnings Per Share (Face value of Rs.10/- each) (for continuing and discontinued operations)					
	1. Basic:	(0.07)	(1.03)	1.16	(2.46)	0.69
	2. Diluted:	(0.07)	(1.03)	1.16	(2.46)	0.68

Notes:

1. Additional information of the Company on standalone basis is as follows:

Sr. No.	Particulars	Three months ended 31/03/2026	Three months ended 31/12/2025	Corresponding Three months ended 31/03/2025	For the year ended 31/03/2026	For the previous year ended 31/03/2025
		(Refer Note 4)	(Unaudited)	(Refer Note 4)	(Audited)	(Audited)
1.	Total Income	1,672.75	1,291.96	1,729.31	5,444.74	5,493.06
2.	Profit before tax	331.85	154.93	364.36	876.77	911.14
3.	Profit after tax	261.63	128.91	277.27	700.01	691.40

2. The above is an extract of the detailed format of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Financial Results for the Quarter and year ended March 31, 2026 are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and the Company's website ([www.piramalpharma.com](http://www.piramalpharma.com)).

3. Exceptional and/or Extraordinary items are adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules.  
 4. The figures for the last quarter of the current financial year are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of third quarter of the current financial year which were subjected to limited review by statutory auditors.

5. The audited consolidated financial results of Piramal Pharma Limited ("the Company") for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on April 28, 2026. The Statutory auditors of the Company have carried out audit of these results.

5. The financial results can also be accessed by scanning the QR code.



Place: Mumbai  
 Date : April 28, 2026

For Piramal Pharma Limited

**Nandini Piramal**  
 Chairperson  
 DIN: 00286092

